Macitentan

CAS 441798-33-0 13 API suppliersSmall Molecule

Overview

Macitentan is an endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It works by preventing the vasoconstriction and proliferation effects of endothelin-1, a potent vasoconstrictor.

API suppliers (13)

Suppliers of Macitentan evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India7China4Netherlands1

Country recorded for 12 of 13 suppliers.

6 of 13 hold a GMP certificate on record in the EU or UK registers

Patent & exclusivity (US)

Per the FDA Orange Book (13 approved US products), the latest listed US patent on Macitentan expires 18 Oct 2029 and exclusivity 28 Aug 2028. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

Pulmonary Arterial HypertensionCardiovascular Diseases
Verified Supplier Partner

Do you supply Macitentan? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.